Related Experiment Video
Updated: Apr 18, 2026
Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
Published on: June 7, 2024
[Breaking immune tolerance in cancer]
Mélanie Desbois1, Stéphane Champiat2, Nathalie Chaput3
1Gustave-Roussy cancer campus, 39, rue Camille-Desmoulins, 94805 Villejuif, France; Gustave-Roussy cancer campus, centre d'investigation clinique biothérapie 1428, Inserm, 39, rue Camille-Desmoulins, 94805 Villejuif, France; Université Paris-Sud, faculté de médecine, 63, rue Gabriel-Péri, 94270 Kremlin-Bicêtre, France; Gustave-Roussy cancer campus, laboratoire d'immunomonitoring en oncologie, UMS 3655 CNRS et US 23 Inserm, 39, rue Camille-Desmoulins, 94805 Villejuif, France.
Abstract:
The discovery and understanding of complex cellular interactions that govern the immune system contributed to the pharmacological targeting of anti-tumor immunity. The activity of immune effector cells, such as NK and T-cells, is regulated by a wide range of activating and inhibiting receptors or ligands. Drugs that target these receptors or ligands can modulate the immune response by exerting antagonistic or agonistic effects. Over the past decade, several immunomodulators have demonstrated clinical effectiveness, and three of them have already been approved for use in oncology. The development of these immunotherapy approaches presented unique challenges for safety and efficacy, requiring revising clinical response criteria and the establishment of guidelines to help oncologists to manage properly inflammatory toxicities. The introduction of these immunotherapies is a revolution in oncology. However, additional efforts in terms of optimizing treatment administration and identification of biomarkers are needed. Identifying the immunodynamics of various immunomodulators should allow a better understanding of anti-tumor and inflammatory mechanisms, and certainly give the opportunity to develop effective therapeutic combinations without potentiating adverse events.
Insights
Immunotherapy harnesses immune cells like NK and T-cells to fight cancer by targeting immune receptors. While approved immunomodulators offer new hope, optimizing treatments and managing side effects remain key challenges.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Cellular interactions in the immune system are crucial for anti-tumor immunity.
- Immune effector cells (NK and T-cells) have regulated activity via receptors and ligands.
- Immunomodulators can target these receptors to modulate immune responses.
Purpose of the Study:
- To review the advancements in pharmacological targeting of anti-tumor immunity.
- To discuss the challenges and successes of immunotherapies in oncology.
- To highlight the need for optimizing treatment and identifying biomarkers.
Main Methods:
- Review of scientific literature on immunomodulators and anti-tumor immunity.
- Analysis of clinical effectiveness and approved immunotherapies in oncology.
- Discussion of safety, efficacy, and management of toxicities.
Main Results:
- Several immunomodulators have shown clinical effectiveness, with three approved for oncology.
- Immunotherapy represents a significant advancement in cancer treatment.
- Challenges include managing inflammatory toxicities and revising clinical response criteria.
Conclusions:
- Further research is needed to optimize treatment administration and identify biomarkers.
- Understanding immunodynamics is essential for developing effective therapeutic combinations.
- Future efforts should focus on enhancing anti-tumor mechanisms while minimizing adverse events.
Related Concept Videos
01:27Tumor Immunotherapy
01:20Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
02:56Treatment Resistant Cancers
01:40Cell-mediated Immune Responses
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies